Implications of cytochrome P450 interactions when prescribing medication for hypertension

被引:87
作者
Flockhart, DA [1 ]
Tanus-Santos, JE
机构
[1] Indiana Univ, Sch Med, Dept Med, Wishard Hosp, OPW 320 1001 W 10th St, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Div Clin Pharmacol, Indianapolis, IN USA
关键词
D O I
10.1001/archinte.162.4.405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many of the estimated 50 million Americans with high blood pressure receive medications for hypertension and for other conditions, placing them at risk for adverse drug interactions. The risk for hypertension and for adverse drug reactions is highest in the elderly, who have the greatest need for pharmacologic therapy. The most important class of drug interactions involves the cytochrome P450 microsomal enzyme system, which handles a variety of xenobiotic substances. A potential for interactions with these enzymes exists with calcium channel blockers, beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers but not with diuretic antihypertensives, which are renally eliminated and more vulnerable to drug interactions that occur in the kidney. This article reviews the cytochrome P450 enzyme system, identifies drugs and foods that have been implicated in metabolic interactions with antihypertensive agents, and suggests measures for reducing the risk of adverse events when drugs are coadministered.
引用
收藏
页码:405 / 412
页数:8
相关论文
共 87 条
  • [31] OXIDATION OF DIHYDROPYRIDINE CALCIUM-CHANNEL BLOCKERS AND ANALOGS BY HUMAN LIVER CYTOCHROME-P-450 IIIA4
    GUENGERICH, FP
    BRIAN, WR
    IWASAKI, M
    SARI, MA
    BAARNHIELM, C
    BERNTSSON, P
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (06) : 1838 - 1844
  • [32] Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity
    Hamelin, BA
    Bouayad, A
    Méthot, J
    Jobin, J
    Desgagnés, P
    Poirier, P
    Allaire, J
    Dumesnil, J
    Turgeon, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (05) : 466 - 477
  • [33] Cytochrome p450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors .1.
    Harvey, AT
    Preskorn, SH
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (04) : 273 - 285
  • [34] The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine
    Heinig, R
    Adelmann, HG
    Ahr, G
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (01) : 57 - 60
  • [35] Clinical pharmacokinetics of nisoldipine coat-core
    Heinig, R
    [J]. CLINICAL PHARMACOKINETICS, 1998, 35 (03) : 191 - 208
  • [36] INDUCTION OF PROPRANOLOL METABOLISM BY RIFAMPICIN
    HERMAN, RJ
    NAKAMURA, K
    WILKINSON, GR
    WOOD, AJJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (05) : 565 - 569
  • [37] Holtbecker N, 1996, DRUG METAB DISPOS, V24, P1121
  • [38] CHANGES IN THE PHARMACOKINETICS AND ELECTROCARDIOGRAPHIC PHARMACODYNAMICS OF TERFENADINE WITH CONCOMITANT ADMINISTRATION OF ERYTHROMYCIN
    HONIG, PK
    WOOSLEY, RL
    ZAMANI, K
    CONNER, DP
    CANTILENA, LR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (03) : 231 - 238
  • [39] Stereoselective metabolism of bisoprolol enantiomers in dogs and humans
    Horikiri, Y
    Suzuki, T
    Mizobe, M
    [J]. LIFE SCIENCES, 1998, 63 (13) : 1097 - 1108
  • [40] Drug interaction between cimetidine and timolol ophthalmic solution: Effect on heart rate and intraocular pressure in healthy Japanese volunteers
    Ishii, Y
    Nakamura, K
    Tsutsumi, K
    Kotegawa, T
    Nakano, S
    Nakatsuka, K
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (02) : 193 - 199